• About us
• Contact

Advertisement

Organisation › Details

Oncurious N.V.

Oncurious NV is a Belgium-based privately held oncology company focused on the development of innovative medicines for the treatment of cancers. The Company is a venture between ThromboGenics NV and VIB, the leading life science research institute in Flanders, Belgium. Oncurious is currently developing a portfolio of next generation immune-oncology assets and targets. The company is already recruiting patients in a Phase I/IIa clinical program with TB-403 for the treatment of medulloblastoma, a rare life-threatening brain tumor that mainly affects children. *

 

	Start	2015-04-14 established jv
	Group	Oxurion (Group)
	Industry	BIOTECH
	Industry 2	TB-403 (BioInvent/ThromboGenics)
	Person	De Haes, Patrik (ThromboGenics 200808– CEO before Roche Diagnostics)
	Region	Leuven (Louvain)
	Country	Belgium
	Street	1 Gaston Geenslaan
	City	3001 Leuven
	Tel	+32-16-751310
		Address record changed: 2024-01-05
Basic data	Employees	n. a.
		* Document for »About Section«: Oncurious N.V.. (9/1/17). "Press Release: Oncurious NV Acquires Unique Portfolio of Next-generation Immuno-oncology Assets from VIB". Leuven.
		Record changed: 2024-02-12

Advertisement

More documents for Oxurion (Group)

• [1] Mogrify Ltd.. (11/2/21). "Press Release: Mogrify Appoints Tom Graney as Non-Executive Director, Audit Chair and Capital Markets Advisor". Cambridge....
• [2] Oxurion N.V.. (5/17/21). "Press Release: Oxurion NV Appoints Tom Graney, CFA as Chief Executive Officer. Patrik De Haes M.D. Becomes Non-executive Chairman". Leuven & Boston, MA....
• [3] Oxurion N.V.. (10/13/20). "Press Release: Oxurion NV Appoints Tom Graney, CFA as Chief Financial Officer". Leuven & Boston, MA....
• [4] Bicycle Therapeutics plc. (8/8/19). "Press Release: Bicycle Therapeutics Reports Second Quarter 2019 Financial Results and Provides Clinical Update". Cambridge & Boston, MA....
• [5] Oxurion N.V.. (9/10/18). "Press Release: Oxurion NV Announces New Euronext Brussels Stock Ticker “OXUR” and Launch of New Website". Leuven....
• [6] Bicycle Therapeutics Ltd.. (5/25/18). "Press Release: Bicycle Therapeutics Announces Clinical Milestone and Expands Collaboration with Thrombogenics". Cambridge & Boston, MA....
• [7] ThromboGenics N.V.. (3/15/18). "Press Release: ThromboGenics Business Update – FY 2017". Leuven....
• [8] ThromboGenics N.V.. (1/26/18). "Press Release: Novartis Pharma AG Holding 5.69% of ThromboGenics Equity Capital". Leuven....
• [9] ThromboGenics N.V.. (12/8/17). "Press Release: Patient Enrolment in Phase II CIRCLE Study Evaluating THR-409 (ocriplasmin) for Non-Proliferative Diabetic Retinopathy (NPDR) Discontinued Due to Slow Recruitment Rate". Leuven....
• [10] ThromboGenics N.V.. (11/8/17). "Press Release: ThromboGenics Strengthens Leadership Team". Leuven....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.